Physician profile
Sam I Hooshmand
NPI 1417310665
$229,256.22
in general payments reported to CMS, 2019-2025
13 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,380 · 2021: $2,690 · 2022: $7,876 · 2023: $28K · 2024: $57K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Consulting Fee: $44K · Travel and Lodging: $25K · Food and Beverage: $8,354 · Education: $10.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,253.50 |
| Consulting Fee | $43,996.50 |
| Travel and Lodging | $24,696.29 |
| Food and Beverage | $8,353.96 |
| Education | $10.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $89,477.86 | 2023-2025 | Briumvi |
| Emd Serono, INC. | $86,111.78 | 2021-2025 | Mavenclad |
| Genentech USA, INC. | $30,923.58 | 2020-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $12,984.35 | 2021-2025 | |
| Amgen INC. | $7,340.61 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $1,314.14 | 2022-2025 | |
| Horizon Therapeutics Plc | $292.35 | 2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $243.27 | 2021-2025 | |
| Roche Products Limited | $211.09 | 2024-2025 | |
| Banner Life Sciences, LLC | $124.87 | 2022 | |
| Celgene Corporation | $95.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $87.02 | 2020 | |
| Biogen, INC. | $50.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Hooshmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.